Question to the Department of Health and Social Care:

To ask Her Majesty’s Government what assessment they have made of the impact of proposals that the pharmaceutical industry should pay entirely for overspends in the Cancer Drugs Fund on the number of medicines that the industry puts forward for possible inclusion in that Fund.

NHS England plans to invest in a new £340 million Cancer Drugs Fund (CDF) to provide early access to cancer drug indications. Under the new process, any drugs that receive either a draft recommendation for routine commissioning or, where uncertainty exists, a recommendation for use within the CDF, will receive interim funding from the CDF from the point of marketing authorisation.

This earlier access to cancer drugs will benefit both patients and the pharmaceutical industry and NHS England believes it is only fair that the pharmaceutical industry makes a contribution if any overspend occurs.

NHS England’s impact assessment will not be completed until the detailed outcomes from the current consultation on the future of the CDF are confirmed.